Compare
CytoDyn Inc. vs Clene Inc. vs Propanc Biopharma, Inc. vs Jyong Biotech Ltd.
| Latest fiscal year | CytoDyn Inc. CYDY | Clene Inc. CLNN | Propanc Biopharma, Inc. PPCB | Jyong Biotech Ltd. MENS |
|---|---|---|---|---|
| Year ended | 2026-05-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $200.0K | n/a | n/a |
| Revenue growth (YoY) | n/a | -41.5% | n/a | n/a |
| Gross margin | n/a | 78.5% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$42.70M | -$26.17M | -$18.86M | -$4.67M |
| EPS (Diluted) | -$0.03 | n/a | -$17.62 | -$0.06 |
| Operating cash flow | -$17.25M | -$18.55M | -$5.68M | -$3.04M |
| Free cash flow | n/a | -$18.59M | -$5.69M | n/a |
| Cash & equivalents | $11.85M | $5.19M | n/a | n/a |
| Total assets | $13.97M | $18.13M | $12.78M | $20.78M |
| Total liabilities | $123.69M | $35.72M | $3.38M | $45.68M |
| Shareholders' equity | -$109.72M | -$17.59M | $9.40M | -$24.91M |
| Return on year-end equity | n/a | n/a | -200.6% | n/a |
| Shares outstanding | 1.37B | 10.85M | 3.31M | 76.03M |
Revenue, most recent five fiscal years
| Fiscal year | CytoDyn Inc. | Clene Inc. | Propanc Biopharma, Inc. | Jyong Biotech Ltd. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-05-31 | $200.0K Ended 2025-12-31 | n/a | n/a |
| 1 year earlier | $266.0K Ended 2022-05-31 | $342.0K Ended 2024-12-31 | n/a | n/a |
| 2 years earlier | $0 Ended 2021-05-31 | $654.0K Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $473.0K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $723.0K Ended 2021-12-31 | n/a | n/a |